Stoke Therapeutics (STOK) Preferred Shares (2018)

Stoke Therapeutics (STOK) recorded quarterly Preferred Shares of $130.3 million in Q4 2018.

Stoke Therapeutics (STOK) Preferred Shares (2018) Analysis & Trends

Stoke Therapeutics' Preferred Shares history runs 1 years deep, the most recent figure standing at $130.3 million for Q4 2018.

In Q4 2018, Preferred Shares changed N/A year-over-year to $130.3 million; the TTM figure through Dec 2018 stood at $130.3 million (changed N/A YoY), while the FY2018 annual figure was $130.3 million, changed N/A from the prior year.
Preferred Shares was $130.3 million for Q4 2018 at Stoke Therapeutics.
In the past five years, Preferred Shares ranged from a high of $130.3 million in Q4 2018 to a low of $130.3 million in Q4 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Stoke Therapeutics	1.95 Bn	1.95 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2018	130.35 Mn